

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Neural Environment in Disease: Glial Responses and Neuroinflammation (Z1)

Scientific Organizers: Richard Daneman, Dorothy Schafer, Michael V. Sofroniew and Vanda A. Lennon

Sponsored by BioLegend, Inc.

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)

Scientific Organizers: Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage

June 16-20, 2019 • Keystone Resort • Keystone, Colorado, USA

Sponsored by BioLegend, Inc., Roche, Ionis Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited

Abstract & Scholarship Deadline: February 13, 2019 / Abstract Deadline: March 13, 2019 / Discounted Registration Deadline: April 16, 2019

SUNDAY, JUNE 16

Arrival and Registration

MONDAY, JUNE 17

Welcome and Keynote Address (Z1)

Li-Huei Tsai, Massachusetts Institute of Technology, USA
Neuron-Glia Interaction in Health and Disease

Welcome and Keynote Address (Z2)

Marc Tessier-Lavigne, Stanford University, USA
Neural Circuits & Neuroregeneration

Neuronal Response to Injury (Z1)

David M. Holtzman, Washington University, USA
Glia-Neuronal Interactions in Modulating Neurodegeneration in Alzheimer's Disease

Eric J. Huang, University of California, San Francisco, USA
Geminal Matrix Hemorrhage

Marc R. Freeman, Vollum Institute, Oregon Health & Science University, USA
Mechanisms of Axon Degeneration

Short Talk(s) Chosen from Abstracts

Aggregation Mediated Toxicity (Z2)

Rudolph E. Tanzi, Massachusetts General Hospital, USA
Amyloid Beta Organoid Model

Valina L. Dawson, Johns Hopkins University School of Medicine, USA
Alpha Synuclein Toxicity in Human Neuronal Cultures

Patrik Verstreken, KU Leuven, Belgium
Tau Toxicity at the Synapse

Short Talk Chosen from Abstracts

Workshop 1 (Z1)

Short Talks Chosen from Abstracts

Workshop 1 (Z2)

Short Talks Chosen from Abstracts

Transmission and Spread of Disease Pathology (Z2)

Xiaobo Mao, Johns Hopkins University, USA
The Mechanism of Pathological alpha-synuclein Transmission

John Collinge, Institute of Neurology, University College London, UK
Prion Neurodegeneration: Towards an Effective Treatment and its Relevance for Alzheimer's Disease

Karina Fog, H. Lundbeck A/S, Denmark

Alpha-synuclein Antibodies as Therapeutics in Aynucleinopathies – How Antibodies affect Cellular Handling of Misfolded alpha-synuclein

Short Talk Chosen from Abstracts

Astrocytes (Z1)

Michael V. Sofroniew, David Geffen School of Medicine at UCLA, USA

Astrocyte Scars do not Prevent Axon Regeneration

Jin-Moo Lee, Washington University, USA
Astrocytosis and Amyloid Plaque Pathogenesis

Cagla Eroglu, Duke University Medical Center, USA

How Do Astrocyte-Synapse Interactions Sculpt Neural Circuits?

Baljit S. Khakh, David Geffen School of Medicine, UCLA, USA

Astrocyte Regulation of Circuitry

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, JUNE 18

Microglia and Innate Immunity (Z1)

Dorothy Schafer, University of Massachusetts Medical School, USA
Microglia Dysregulation in Multiple Sclerosis

Kim N. Green, University of California, Irvine, USA

Microglial Regulation of Alzheimer's Disease

Robyn S. Klein, Washington University School of Medicine, USA

Infections of the CNS

Sarkis K. Mazmanian, California Institute of Technology, USA

The Gut Microbiome and Neurodegeneration

Short Talk(s) Chosen from Abstracts

New Therapeutic Opportunities (Z2)

Frank W. Rigo, Ionis Pharmaceuticals, USA

Antisense-based Strategies

Eric J. Huang, University of California, San Francisco, USA

Microglia and Neurologic Disease

Don W. Cleveland, University of California, San Diego, USA

Gene Silencing Therapy for Neurodegenerative Disease

Li Gan, University of California, San Francisco, USA

Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

Workshop 2 (Z1)

Short Talks Chosen from Abstracts

Developing Effective Preclinical Disease Models (Z2)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Neural Environment in Disease: Glial Responses and Neuroinflammation (Z1)

Scientific Organizers: Richard Daneman, Dorothy Schafer, Michael V. Sofroniew and Vanda A. Lennon

Sponsored by BioLegend, Inc.

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)

Scientific Organizers: Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage

June 16-20, 2019 • Keystone Resort • Keystone, Colorado, USA

Sponsored by BioLegend, Inc., Roche, Ionis Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited

Abstract & Scholarship Deadline: February 13, 2019 / Abstract Deadline: March 13, 2019 / Discounted Registration Deadline: April 16, 2019

Cathleen Lutz, The Jackson Laboratory, USA
Preclinical Mouse Models of Neurodegenerative Diseases Spinal Muscular Atrophy (SMA), Friedreich's Ataxia, Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobe Dementia (FTD)

Elena Cattaneo, University of Milano, Italy
Organiod Models of Triple Repeat Diseases

Fred (Rusty) H. Gage, The Salk Institute for Biological Studies, USA
iPSC to Study Repair and Neurodegeneration

Short Talk Chosen from Abstracts

Blood Brain Barrier (Z1)

Richard Daneman, University of California, San Diego, USA
Regulation of the Blood-Brain Barrier in Health and Disease

Alexandre Prat, Montreal Neurological Institute, Canada
Talk Title to be Announced

Eric V. Shusta, University of Wisconsin, Madison, USA
Modeling the BBB in iPSCs

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, JUNE 19

Glymphatics, Lymphatics and Wound Healing (Z1)

Kari K. Alitalo, University of Helsinki, Finland
CNS Lymphatics

Iben Lundgaard, University of Lund, Sweden
Glymphatics

Maria Lehtinen, Boston Children's Hospital, Harvard Medical School, USA
CSF Regulation

Julie Siegenthaler, University of Colorado Denver, USA
Wound Healing

Short Talk(s) Chosen from Abstracts

Translating Therapeutics for Neurodegeneration to the Clinic (Z2)

Joseph W. Lewcock, Denali Therapeutics, USA
Therapeutic Strategies based on Human Genetics

Christopher E. Henderson, Biogen Inc., USA
Novel Therapeutics for Neurodegenerative Disease

Matthew Kennedy, Merck Research Labs, USA
Discovery and Development of LRRK2 Inhibitors

David V. Hansen, Genentech, Inc., USA
Microglial Activation States in Alzheimer's Disease

Short Talk(s) Chosen from Abstracts

Round Table Discussion from Industry and Academia – Challenges and Opportunities (Z2)

Adaptive Immune Responses (Z1)

Vanda A. Lennon, Mayo Clinic, USA
Astrocytic and Oligodendroglial Autoimmunity

Daniel S. Reich, NINDS, National Institutes of Health, USA
Imaging Lesion Repair in Multiple Sclerosis

Alexander Flugel, University of Göttingen, Germany
T-Cell Interaction with Resident CNS Cells during Autoimmune Disease

Short Talk Chosen from Abstracts

Molecular Mechanisms of ALS/FTD (Z2)

Aaron D. Gitler, Stanford University School of Medicine, USA
Expanding Mechanisms and Therapeutic Targets for Neurodegenerative Disease

Clotilde Lagier-Tourenne, Massachusetts General Hospital, USA
Molecular Mechanisms of Disease in ALS and FTD

Gene W. Yeo, University of California, San Diego, USA
Protein-RNA and Stress Granules Dysregulation in ALS

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, JUNE 20

Oligodendrocytes (Z1)

David H. Rowitch, University of Cambridge, UK
Functional Diversity of Astrocytes

Kelly Monk, Oregon Health & Science University, USA
Molecular and Genetic Mechanisms of Myelin Formation and Repair

Rita Balice-Gordon, Sanofi, Inc., USA
Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

Drivers of Synaptic Loss in Disease (Z2)

Paul F. Worley, Johns Hopkins School of Medicine, USA
NPTX2, Synaptotoxicity and Cognitive Dysfunction in AD

Beth Stevens, Children's Hospital Boston, USA
How Microglia Prune Synapses

Karen Hsiao Ashe, University of Minnesota, USA
Synaptic and Cognitive Dysfunction from Non-fibrillar Tau

Shanthini Sockanathan, Johns Hopkins University School of Medicine, USA
Mechanisms of Regulated GPI-anchored Protein Release in Neurodegeneration

Short Talk Chosen from Abstracts

Workshop 3 (Z1)

Short Talks Chosen from Abstracts

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Neural Environment in Disease: Glial Responses and Neuroinflammation (Z1)

Scientific Organizers: Richard Daneman, Dorothy Schafer, Michael V. Sofroniew and Vanda A. Lennon

Sponsored by BioLegend, Inc.

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)

Scientific Organizers: Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage

June 16-20, 2019 • Keystone Resort • Keystone, Colorado, USA

Sponsored by BioLegend, Inc., Roche, Ionis Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited

Abstract & Scholarship Deadline: February 13, 2019 / Abstract Deadline: March 13, 2019 / Discounted Registration Deadline: April 16, 2019

Workshop 2 (Z2)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Neural Environment in Disease: Glial Responses and Neuroinflammation (Z1)

Scientific Organizers: Richard Daneman, Dorothy Schafer, Michael V. Sofroniew and Vanda A. Lennon

Sponsored by BioLegend, Inc.

Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)

Scientific Organizers: Valina L. Dawson, Joseph W. Lewcock and Fred H. Gage

June 16-20, 2019 • Keystone Resort • Keystone, Colorado, USA

Sponsored by BioLegend, Inc., Roche, Ionis Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited

Abstract & Scholarship Deadline: February 13, 2019 / Abstract Deadline: March 13, 2019 / Discounted Registration Deadline: April 16, 2019

Short Talks Chosen from Abstracts

Hot Topics (Z1)

Speaker to be Announced

Speaker to be Announced

Speaker to be Announced

Glial Contributors to Neurodegeneration (Z2)

Mathew M. Blurton-Jones, University of California, Irvine, USA

*Generation and Use of iPSC-derived Microglia to Study
Neurodegenerative Diseases*

Katerina Akassoglou, Gladstone Institutes & University of California,
San Francisco, USA

Neurovascular Interactions: Mechanisms, Imaging, Therapeutics

Sandeep Robert Datta, Harvard Medical School, USA

The MS4A Gene Family in Alzheimer's Disease

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Z1)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Z2)

FRIDAY, JUNE 21

Departure